Pharmahungary Group won an SME Instrument Phase I grant with an innovative in-house R&D project, Vezics, www.vezics.com.
Budapest, Hungary, February 7, 2019. Pharmahungary Group won an SME Instrument Phase I grant with an innovative in-house R&D project, Vezics, www.vezics.com. Vezics is a highly efficient, scalable chromatography platform for high-quality exosome isolation developed in collaboration with Semmelweis University, Budapest, Hungary in the scope of the National Heart Program of Hungary.
Cell-derived vesicles known as exosomes were first discovered more than 30 years ago, but received little attention in the first 25 years after their discovery. In the past decade, however, exosomes receive exponentially growing attention due to their recently understood significance as key elements facilitating intercellular communication. „Despite all their potential in diagnostic and therapeutic use, the transition of exosome-based applications from lab to clinic is hindered by a number of technical barriers. The greatest of these barriers is probably the lack of a gold standard, optimal method and technology to isolate exosomes from bodily fluids that is necessary for all downstream applications.” said Zoltán Giricz, PharmD, PhD, Translational Program Director and Vezics project leader of Pharmahungary Group. “Despite the enormous interest in the role of exosomes in cancer and other diseases, and their use as biomarkers for diagnosis and as therapeutic tools, there is no consensus on reliable protocols for their isolation. This constitutes probably the greatest barrier in realizing exosomes’ full potential.” added Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group.
With winning the highly competitive SME Instrument grant Pharmahungary Group will further develop Vezics into market-ready high-quality exosome isolation platform. For more information on Vezics please visit www.vezics.com or contact us directly for partnership opportunities at businessdevelopment@pharmahungary.com.
About Pharmahungary Group
Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2003.
- Preclinical R&D services: from in vitro to in vivo studies including custom designed, co-morbidity, and large animal models, e.g. Göttingen minipigs, focusing on but not limited to cardiovascular, metabolic, and renal disease models.
- Clinical R&D services: full management of clinical trials with Medical Devices including In Vitro Diagnostics, ATMPs, Investigator Initiated Trials, and niche trials that need strong scientific and regulatory consulting, e.g. clinical trials on sensitive patient population.
- In-house R&D projects: several IP protected drug development projects as well as novel supporting technologies for acute and chronic ischemic injuries, e.g. myocardial infarctions, heart failure, atherosclerosis
Contact Pharmahungary Group
Andras Nogradi, MSc, Business Development Manager, Graphisoft Park, Zahony str. 7., Budapest, H-1031, Hungary, European Union. e-mail: andras.nogradi@pharmahungary.com. More information: www.pharmahungary.com
